Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19

Andrea Mazzanti; Martina Briani; Deni Kukavica; Francesca Bulian; Stefano Marelli; Alessandro Trancuccio; Nicola Monteforte; Tommaso Manciulli; Massimo Morini; Annalisa Carlucci; Giacomo Viggiani; Francesco Cannata; Sara Negri; Raffaella Bloise; Mirella Memmi; Patrick Gambelli; Andrea Carbone; Martina Molteni; Raffaella Bianchini; Rita Salgarello; Silvia Sozzi; Pasquale De Cata; Francesco Fanfulla; Piero Ceriana; Carlo Locatelli; Carlo Napolitano; Luca Chiovato; Luca Tomasi; Giulio G. Stefanini; Gianluigi Condorelli; Silvia G. Priori

doi:10.1161/CIRCULATIONAHA.120.048476

Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19

Andrea Mazzanti, Martina Briani, Deni Kukavica, Francesca Bulian, Stefano Marelli, Alessandro Trancuccio, Nicola Monteforte, Tommaso Manciulli, Massimo Morini, Annalisa Carlucci, Giacomo Viggiani, Francesco Cannata, Sara Negri, Raffaella Bloise, Mirella Memmi, Patrick Gambelli, Andrea Carbone, Martina Molteni, Raffaella Bianchini, Rita SalgarelloSilvia Sozzi, Pasquale De Cata, Francesco Fanfulla, Piero Ceriana, Carlo Locatelli, Carlo Napolitano, Luca Chiovato, Luca Tomasi, Giulio G. Stefanini, Gianluigi Condorelli, Silvia G. Priori

Research output: Contribution to journal › Article › peer-review

Abstract

Hydroxychloroquine is currently prescribed in many countries as a treatment for patients with coronavirus disease 2019 (COVID-19). The notion that hydroxychloroquine blocks the hERG (human ether-a-go-go-related gene) potassium channel, potentially leading to QT interval prolongation and arrhythmias, mitigates the enthusiasm for the compound. Recent studies conducted on cohorts of COVID-19 patients treated with hydroxychloroquine reported different signals, ranging from serious concern related to 20% of patients with major corrected QT (QTc) interval prolongation,1 to more reassuring data.2

Original language	English
Pages (from-to)	513-515
Number of pages	3
Journal	Circulation
Volume	142
Issue number	5
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.120.048476
Publication status	Published - Aug 4 2020

Keywords

arrhythmia
COVID-19
hydroxychloroquine
long QT syndrome

Access to Document

10.1161/CIRCULATIONAHA.120.048476

Cite this

Mazzanti, A., Briani, M., Kukavica, D., Bulian, F., Marelli, S., Trancuccio, A., Monteforte, N., Manciulli, T., Morini, M., Carlucci, A., Viggiani, G., Cannata, F., Negri, S., Bloise, R., Memmi, M., Gambelli, P., Carbone, A., Molteni, M., Bianchini, R., ... Priori, S. G. (2020). Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19. Circulation, 142(5), 513-515. https://doi.org/10.1161/CIRCULATIONAHA.120.048476

Mazzanti, A, Briani, M, Kukavica, D, Bulian, F, Marelli, S, Trancuccio, A, Monteforte, N, Manciulli, T, Morini, M, Carlucci, A, Viggiani, G, Cannata, F, Negri, S , Bloise, R , Memmi, M , Gambelli, P, Carbone, A, Molteni, M, Bianchini, R, Salgarello, R, Sozzi, S, De Cata, P , Fanfulla, F , Ceriana, P , Locatelli, C, Napolitano, C, Chiovato, L, Tomasi, L, Stefanini, GG , Condorelli, G & Priori, SG 2020, 'Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19', Circulation, vol. 142, no. 5, pp. 513-515. https://doi.org/10.1161/CIRCULATIONAHA.120.048476

@article{23f5a1dcfdf3412fa0e94be1004ad221,

title = "Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19",

abstract = "Hydroxychloroquine is currently prescribed in many countries as a treatment for patients with coronavirus disease 2019 (COVID-19). The notion that hydroxychloroquine blocks the hERG (human ether-a-go-go-related gene) potassium channel, potentially leading to QT interval prolongation and arrhythmias, mitigates the enthusiasm for the compound. Recent studies conducted on cohorts of COVID-19 patients treated with hydroxychloroquine reported different signals, ranging from serious concern related to 20% of patients with major corrected QT (QTc) interval prolongation,1 to more reassuring data.2",

keywords = "arrhythmia, COVID-19, hydroxychloroquine, long QT syndrome",

author = "Andrea Mazzanti and Martina Briani and Deni Kukavica and Francesca Bulian and Stefano Marelli and Alessandro Trancuccio and Nicola Monteforte and Tommaso Manciulli and Massimo Morini and Annalisa Carlucci and Giacomo Viggiani and Francesco Cannata and Sara Negri and Raffaella Bloise and Mirella Memmi and Patrick Gambelli and Andrea Carbone and Martina Molteni and Raffaella Bianchini and Rita Salgarello and Silvia Sozzi and {De Cata}, Pasquale and Francesco Fanfulla and Piero Ceriana and Carlo Locatelli and Carlo Napolitano and Luca Chiovato and Luca Tomasi and Stefanini, {Giulio G.} and Gianluigi Condorelli and Priori, {Silvia G.}",

year = "2020",

month = aug,

day = "4",

doi = "10.1161/CIRCULATIONAHA.120.048476",

language = "English",

volume = "142",

pages = "513--515",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19

AU - Mazzanti, Andrea

AU - Briani, Martina

AU - Kukavica, Deni

AU - Bulian, Francesca

AU - Marelli, Stefano

AU - Trancuccio, Alessandro

AU - Monteforte, Nicola

AU - Manciulli, Tommaso

AU - Morini, Massimo

AU - Carlucci, Annalisa

AU - Viggiani, Giacomo

AU - Cannata, Francesco

AU - Negri, Sara

AU - Bloise, Raffaella

AU - Memmi, Mirella

AU - Gambelli, Patrick

AU - Carbone, Andrea

AU - Molteni, Martina

AU - Bianchini, Raffaella

AU - Salgarello, Rita

AU - Sozzi, Silvia

AU - De Cata, Pasquale

AU - Fanfulla, Francesco

AU - Ceriana, Piero

AU - Locatelli, Carlo

AU - Napolitano, Carlo

AU - Chiovato, Luca

AU - Tomasi, Luca

AU - Stefanini, Giulio G.

AU - Condorelli, Gianluigi

AU - Priori, Silvia G.

PY - 2020/8/4

Y1 - 2020/8/4

N2 - Hydroxychloroquine is currently prescribed in many countries as a treatment for patients with coronavirus disease 2019 (COVID-19). The notion that hydroxychloroquine blocks the hERG (human ether-a-go-go-related gene) potassium channel, potentially leading to QT interval prolongation and arrhythmias, mitigates the enthusiasm for the compound. Recent studies conducted on cohorts of COVID-19 patients treated with hydroxychloroquine reported different signals, ranging from serious concern related to 20% of patients with major corrected QT (QTc) interval prolongation,1 to more reassuring data.2

AB - Hydroxychloroquine is currently prescribed in many countries as a treatment for patients with coronavirus disease 2019 (COVID-19). The notion that hydroxychloroquine blocks the hERG (human ether-a-go-go-related gene) potassium channel, potentially leading to QT interval prolongation and arrhythmias, mitigates the enthusiasm for the compound. Recent studies conducted on cohorts of COVID-19 patients treated with hydroxychloroquine reported different signals, ranging from serious concern related to 20% of patients with major corrected QT (QTc) interval prolongation,1 to more reassuring data.2

KW - arrhythmia

KW - COVID-19

KW - hydroxychloroquine

KW - long QT syndrome

U2 - 10.1161/CIRCULATIONAHA.120.048476

DO - 10.1161/CIRCULATIONAHA.120.048476

M3 - Article

SN - 0009-7322

VL - 142

SP - 513

EP - 515

JO - Circulation

JF - Circulation

IS - 5

ER -

Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19

Abstract

Keywords

Access to Document

Fingerprint

Cite this